Free tool
FAERS Monitor: Xtandi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203415 or its brand name (Xtandi, Enzalutamide). Reports on generic versions are filed under their own applications.
Reports
58,866
Serious
36,319
62% of reports
Hospitalization
11,199
Death reported
11,400
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue10,332
- death7,715
- malignant neoplasm progression5,499
- prostatic specific antigen increased4,361
- asthenia4,207
- drug ineffective4,067
- hot flush3,932
- decreased appetite3,421
- nausea3,270
- dizziness3,172
- diarrhoea2,813
- back pain2,307
- arthralgia2,170
- underdose2,090
- fall1,847
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 244 |
| 2013 | 2,555 |
| 2014 | 4,441 |
| 2015 | 5,923 |
| 2016 | 7,914 |
| 2017 | 10,285 |
| 2018 | 7,756 |
| 2019 | 3,394 |
| 2020 | 2,641 |
| 2021 | 2,409 |
| 2022 | 2,608 |
| 2023 | 2,329 |
| 2024 | 2,508 |
| 2025 | 2,634 |
| 2026 | 1,225 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,995,293 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| prostatic specific antigen increasedSignal | 4,361 | 164.9 | 159.3 | 486,111 |
| malignant neoplasm progressionSignal | 5,499 | 20.2 | 19.7 | 95,503 |
| hot flushSignal | 3,932 | 19.6 | 19.0 | 66,045 |
| underdoseSignal | 2,090 | 10.5 | 10.1 | 17,505 |
| decreased appetiteSignal | 3,421 | 5.3 | 5.2 | 11,973 |
| fatigueSignal | 10,332 | 4.8 | 4.7 | 31,763 |
| astheniaSignal | 4,207 | 4.0 | 3.9 | 9,653 |
| back painSignal | 2,307 | 3.6 | 3.4 | 4,278 |
| deathSignal | 7,715 | 3.2 | 3.2 | 12,197 |
| dizzinessSignal | 3,172 | 2.3 | 2.2 | 2,320 |
| fall | 1,847 | 2.0 | 1.9 | 916 |
| arthralgia | 2,170 | 1.9 | 1.8 | 889 |
| diarrhoea | 2,813 | 1.6 | 1.5 | 579 |
| nausea | 3,270 | 1.5 | 1.4 | 523 |
| drug ineffective | 4,067 | 1.1 | 1.1 | 41 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.